Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Locally Advanced or Metastatic Breast Cancer
Interventions: DRUG: Taxane plus Intermittent Capecitabine|DRUG: Utidelone plus Intermittent Capecitabine|DRUG: Taxane plus Metronomic Capecitabine|DRUG: Utidelone plus Metronomic Capecitabine
Sponsor: Sun Yat-sen University
Collaborators: Chengdu Biostar Pharmaceuticals